The International Linked Clinical Trials (iLCT) programme
As Chair of the iLCT committee since the programme was created in 2012, Van Andel Institute’s Professor Patrik Brundin has been instrumental in its success and the two organisations’ partnership has been a vital ingredient in this flourishing programme. Professor Brundin explains the role of the iLCT committee.
Priority Projects
Find out moreThe iLCT initiative already has momentum. There are now over 40 drugs prioritised, with 17 already in or about to go into clinical trial, and 44 being actively pursued. Our goal is to ensure we can commit more therapies to trial to create new, effective treatments that slow, stop or even reverse disease progression for people living with Parkinson’s.
Australian Parkinson’s Mission (APM)
In January 2019, the Australian Parkinson’s Mission – an international collaboration between the Garvan Institute of Medical Research, Shake It Up Australia Foundation, Parkinson’s Australia, Cure Parkinson’s and the Michael J. Fox Foundation for Parkinson’s – was awarded a A$30 million government grant to identify and fast-track better treatments for Parkinson’s. This innovative Australian-led programme of research expands the global Linked Clinical Trials programme spearheaded by Cure Parkinson’s and establishes a first step towards personalised medicine providing an opportunity to deliver multiple clinical trials that incorporate advanced genetic and biomarker studies in a way that has not been done before.